LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Bio2RDF identifier
NCT01726738
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01726738
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This phase II study in ...... nation will also be assessed.
brief title [clinicaltrials_vocabulary:brief-title]
LCCC 1128: Open Label Phase II ...... inome and Functional Mutations
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Kinase Expression One year post treatment [clinicaltrials_resource:107946b9cd54f3b0fd5c9f13f11f7270]
Kinase Expression One year post treatment [clinicaltrials_resource:3b0c5f10116cbf5bd5480787a43fb17a]
Kinase Expression One year post treatment [clinicaltrials_resource:b5c2f0b761c23399f776eca4057f76eb]
Kinase Expression One year post treatment [clinicaltrials_resource:c186c0388ca39a80f5e37e7613220039]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2015-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
The present phase II st ...... with
mass spectrometry.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2012-11-08T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
BRAF Mutant
Dabrafenib
Resistance
Sequencing
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-08-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01726738
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
LCCC 1128: Open Label Phase II ...... inome and Functional Mutations
org study id [clinicaltrials_vocabulary:org-study-id]
overall contact [clinicaltrials_vocabulary:overall-contact]
overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2014-10-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2012-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-08-01T00:00:00Z
identifier
clinicaltrials:NCT01726738